Back

Renal Outcomes in PARAGLIDE-HF and PARAGON-HF

25 August 2023 (08:45 - 09:00)
Organised by: Logo
Congress Presentation Part of: Clinical trial updates on heart failure Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Muthiah Vaduganathan

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
EMPEROR - Empagliflozin in Patients with Chronic Heart Failure
Professor M. Packer (Dallas, US)
Slides Video
Presentation thumbnail
Effects of Dapagliflozin in Patients with Heart Failure and Deterioration of Kidney Function Below eGFR 25ml/min/1.73m^2
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
STRONG-HF
Professor P. Ponikowski (Wroclaw, PL)
Slides Video
Presentation thumbnail
OPT-PACE - Optimising therapy in patients with pacemakers
Doctor K. Witte (Leeds, GB)
Slides Video
Presentation thumbnail
The ADVOR trial: update on renal interactions
Doctor J. Dauw (Aalst, BE)
Slides Video

Access the full session

Session thumbnail
Clinical trial updates on heart failure
Video

The Event

Event poster

ESC Congress 2023

25 August 2023 08:45 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction according to background MRA therapy: a pooled analysis of PARAGLIDE-HF and PARAGON-HF
thumbnail
Congress Session
Clinical trial updates on heart failure
thumbnail
Congress Presentation
Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources